Linette Castillo Pichardo
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stilbenes | 5 | 2016 | 44 | 1.300 |
Why?
|
| Vitis | 4 | 2016 | 37 | 1.040 |
Why?
|
| Breast Neoplasms | 6 | 2017 | 1723 | 0.540 |
Why?
|
| Catechin | 3 | 2016 | 39 | 0.500 |
Why?
|
| Quercetin | 3 | 2016 | 46 | 0.490 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2015 | 465 | 0.470 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2015 | 241 | 0.470 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2016 | 299 | 0.420 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 65 | 0.370 |
Why?
|
| Carbazoles | 4 | 2018 | 49 | 0.360 |
Why?
|
| Quinazolines | 1 | 2012 | 38 | 0.360 |
Why?
|
| Mice | 7 | 2017 | 6644 | 0.360 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 183 | 0.350 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 1019 | 0.320 |
Why?
|
| Plant Extracts | 1 | 2013 | 302 | 0.310 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2009 | 22 | 0.300 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 49 | 0.290 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2009 | 69 | 0.290 |
Why?
|
| rac1 GTP-Binding Protein | 3 | 2018 | 50 | 0.250 |
Why?
|
| Cell Line, Tumor | 8 | 2018 | 2676 | 0.240 |
Why?
|
| Pyrimidines | 3 | 2017 | 139 | 0.220 |
Why?
|
| Cell Proliferation | 6 | 2018 | 1455 | 0.180 |
Why?
|
| Neoplasm Metastasis | 3 | 2017 | 237 | 0.150 |
Why?
|
| Animals | 8 | 2017 | 16992 | 0.150 |
Why?
|
| Drug Design | 2 | 2018 | 186 | 0.140 |
Why?
|
| Mice, Nude | 3 | 2016 | 408 | 0.140 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2017 | 25 | 0.130 |
Why?
|
| Signal Transduction | 3 | 2017 | 2157 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 611 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 139 | 0.120 |
Why?
|
| Mice, SCID | 2 | 2016 | 158 | 0.120 |
Why?
|
| Genistein | 1 | 2016 | 45 | 0.120 |
Why?
|
| Breast | 1 | 2016 | 139 | 0.110 |
Why?
|
| Reference Standards | 1 | 2014 | 55 | 0.110 |
Why?
|
| Calibration | 1 | 2014 | 63 | 0.110 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2015 | 26 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 134 | 0.110 |
Why?
|
| Pregnenolone | 1 | 2014 | 17 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 347 | 0.100 |
Why?
|
| Female | 9 | 2017 | 24698 | 0.100 |
Why?
|
| Organometallic Compounds | 1 | 2014 | 71 | 0.100 |
Why?
|
| Mice, Hairless | 1 | 2013 | 7 | 0.100 |
Why?
|
| p21-Activated Kinases | 1 | 2013 | 21 | 0.100 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 39 | 0.100 |
Why?
|
| Molecular Structure | 1 | 2014 | 570 | 0.100 |
Why?
|
| Apoptosis | 2 | 2012 | 1568 | 0.090 |
Why?
|
| Cell Cycle | 2 | 2016 | 346 | 0.090 |
Why?
|
| Adenylate Kinase | 1 | 2012 | 14 | 0.090 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 121 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 51 | 0.090 |
Why?
|
| Sirolimus | 1 | 2012 | 70 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2012 | 227 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 458 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2016 | 518 | 0.080 |
Why?
|
| Cell Survival | 3 | 2017 | 945 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1070 | 0.060 |
Why?
|
| Humans | 8 | 2018 | 43102 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2009 | 358 | 0.060 |
Why?
|
| Cell Movement | 2 | 2018 | 655 | 0.050 |
Why?
|
| Binding Sites | 2 | 2018 | 671 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2018 | 423 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 506 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 68 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 59 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 84 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 456 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 317 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 195 | 0.030 |
Why?
|
| Aminoquinolines | 1 | 2012 | 17 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 28 | 0.020 |
Why?
|
| Kidney | 1 | 2014 | 372 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1081 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 296 | 0.020 |
Why?
|
| Liver | 1 | 2014 | 511 | 0.020 |
Why?
|